arXiv subjects

Lior Epstein

Publications and source records attributed to Lior Epstein.

3 recordsLinked to original sources

arXiv2026

Adapting the TG-43 formalism for use in Diffusing alpha-emitters Radiation Therapy

Background: Diffusing alpha-emitters Radiation Therapy ("Alpha DaRT") enables the treatment of solid tumors using alpha particles. In Alpha DaRT, the tumor dose distribution is mainly dictated by the diffusion of the decay products of $^{224}$Ra. Due to the inherently different mechanism of dose delivery of the Alpha-DaRT source compared to sources emitting only electrons or photons, the conventional formalism of TG-43 cannot be directly applied to Alpha DaRT. Purpose: To adapt the TG-43 formalism to be used with the Alpha-DaRT model, with the specific aim of allowing commercial treatment-planning software packages to be used for Alpha-DaRT treatment planning. Methods: The effective dose rate is defined, along with an activity conversion factor. These, together with a numerical calculation that solves the model equations, allow implementing the Alpha-DaRT model predictions into the TG-43 formalism. Results: An example of calculated $F(r, \theta)$ and $g_L(r)$ tables is presented for an Alpha-DaRT treatment scenario, with the model parameters representing preclinical data on squamous cell carcinoma. Conclusions: Commercial software can be used for Alpha-DaRT treatment planning. However, the generated $F(r, \theta)$ and $g_L(r)$ tables depend on tissue parameters, as well as treatment duration, and so these tables should be generated on a case-by-case basis.

physics.med-ph↗

arXiv2025

Diffusing Alpha-emitters Radiation Therapy: In vivo Measurements of Effective Diffusion and Clearance Rates Across Multiple Tumor Types

Diffusing alpha-emitters radiation therapy (Alpha-DaRT) is a new modality that uses alpha particles to treat solid tumors. Alpha-DaRT employs interstitial sources loaded with low activities of Radium-224, which release a chain of short-lived alpha-emitters diffusing over a few millimeters around each source. Alpha-DaRT dosimetry is described, to first order, by a framework called the diffusion-leakage (DL) model. The aim of this work is to estimate the tumor-specific parameters of the DL model from in-vivo studies on multiple histological cancer types. Autoradiography studies with phosphor imaging were conducted on 113 mice-borne tumors from 10 cancer cell lines. An observable, referred to as the effective diffusion length, Leff, was extracted from images of histological slices obtained using phosphor screens. The tumor and Alpha-DaRT source activities were measured after excision with a gamma counter to estimate the probability of Lead-212 clearance from the tumor by the blood, Pleak(Pb). The measured values of Leff are in the range of 0.2-0.7 mm across different tumor types and sizes. Pleak(Pb) is between 10% and 90% for all measured tumors, and it generally decreases in magnitude and spread for larger tumors. The measured values of Leff and Pleak(Pb) and associated dose calculations indicate that hexagonal Alpha-DaRT source lattices of ~4 mm spacing with muCi-scale Radium-224 activities can lead to effective coverage of the tumor volume with therapeutic dose levels, with considerable margin to compensate for local variations in diffusion and leakage.

physics.med-ph↗

arXiv2023

The low-LET radiation contribution to the tumor dose in diffusing alpha-emitters radiation therapy

Diffusing alpha-emitters Radiation Therapy (Alpha DaRT) enables the use of alpha particles for the treatment of solid tumors. It employs interstitial sources carrying a few uCi of Ra-224, designed to release its short-lived progeny, which emit alpha particles, beta, Auger, and conversion electrons, x- and gamma rays. These atoms diffuse around the source and create a lethal high-dose region, measuring a few mm in diameter. Previous studies focused on the alpha dose alone. This work addresses the electron and photon contributed by the diffusing atoms and by the atoms on the source surface, for both a single source and multi-source lattices. This allows to evaluate the low-LET contribution to the dose and demonstrate the sparing of surrounding healthy tissue. The dose is calculated using Monte Carlo codes. We compare the results of a simple line-source to those of a full simulation, which implements a realistic source geometry and the spread of the diffusing atoms. We consider two extreme scenarios: low diffusion and high Pb-212 leakage, and high diffusion and low leakage. The low-LET dose in source lattices is calculated by superposition of single-source contributions. We found that for sources carrying 3 uCi/cm Ra-224 arranged in a hexagonal lattice with 4 mm spacing, the minimal low-LET dose between sources is 18-30 Gy for the two scenarios and is dominated by the beta contribution. The low-LET dose drops below 5 Gy 3 mm away from the lattice. The accuracy of the line-source approximation is 15% for the total low-LET dose over clinically relevant distances (2-4 mm). For 3 uCi/cm Ra-224 sources, the contribution of the low-LET dose can reduce cell survival by up to 2-3 orders of magnitude. Increasing source activities by a factor of 5 can bring the low-LET dose to therapeutic levels leading to a self-boosted configuration, and potentially allowing to increase the lattice spacing.

physics.med-ph↗